Oramed Pharmaceuticals Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Oramed Pharmaceuticals Inc's ROA in the second quarter of 2026?
Oramed Pharmaceuticals Inc achieved a return on average assets (ROA) of 64.02 % in its second quarter of 2026, this is above ORMP's average return on assets of 19.46%.
Oramed Pharmaceuticals Inc assets over the 12 months ending in its second quarter of 2026 are valued at $273 million

ROA has improved compared to 49.68% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 16 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 74, from total ROA ranking in the first quarter of 2026 at 144.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	127.3 %	81.43 %	50.15 %	33.26 %	-12.28 %
Y / Y Net Income Change	489.41 %	-	-	-	44.07 %
Net Income (TTM) in million	175	110	64	44	-24
Return On Assets (TTM)	64.02 %	49.68 %	33.48 %	25.53 %	-15.31 %
ORMP's Total Ranking	# 74	# 144	# 170	# 3458	# 3562
Total Assets (TTM) in million	370	269	233	221	163
Seq. Total Assets Change	37.49 %	15.31 %	5.57 %	35.81 %	9.75 %
Seq. Net Income Change	104.01 %	282.76 %	-79.32 %	264.92 %	-

ORMP's 5 Years Annual ROA >> Back to ORMP Management Effectiveness >> Compare ORMP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 8
Sector	# 17
Overall	# 52

Return On Assets Statistics
High	Average	Low
68.37 %	19.46 %	-17.78 %
(Aug 31 2013)		(Mar 31 2023)

Financial Statements
Oramed Pharmaceuticals Inc's Assets	$ 370 million	ORMP's Balance sheet
Oramed Pharmaceuticals Inc's Income	$ 78 million	Quarterly ORMP's Income Statement
ORMP's Income by Division		See ORMP's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Aug 31 2021) FY 2021
Y / Y Total Assets Change	5.22 %	-51.59 %	1.52 %	86.42 %	279.74 %
Total Assets in million	163	155	321	316	169
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	64	-19	6	-38	-23
Annual Return On Assets	39.18 %	-12.27 %	1.72 %	-11.95 %	-13.56 %

ORMP's 5 Years Annual ROA >> Back to ORMP Management Effectiveness >> Compare ORMP ROA to its Competitors

Comment on ORMP's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 39.18 % compared to prior year, due to annual net income growth of % to $64.02 million, while value of Oramed Pharmaceuticals Inc's overall assets grew just by 5.22 % to $163.39 million, compared to $163.39 a year before.

More Return On Assets Ratios
ORMP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ORMP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ORMP's Competitors
Subscribers only: Roa for Oramed Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for ORMP's Customers

You may also want to know
ORMP's Roi	ORMP's Inventory Turnover Ratio	ORMP's Growth Rates	ORMP's Dividend Comparisons
	ORMP's Profitability Ratios	ORMP's Asset Turnover Ratio	ORMP's Dividend Growth
ORMP's Roe	ORMP's Valuation Ratios	ORMP's Financial Strength Ratios	ORMP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Kyntra Bio Inc	156.80 %
Vor Biopharma Inc	154.23 %
Glucotrack Inc	151.40 %
Capforce Inc	141.40 %
Protagenic Therapeutics Inc new	137.58 %
Elutia Inc	108.72 %
Silexion Therapeutics Corp	99.09 %
Arbutus Biopharma Corp	96.04 %
Pulmatrix Inc	94.81 %
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Oncotelic Therapeutics Inc	81.75 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %

Date modified: 2026-08-14T05:15:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.